No Data
Xingqi Pharmaceutical Gets Nod to Trial Eye Drops; Shares Up 4%
Shenyang Xingqi Pharmaceutical (300573.SZ): SQ-22031 eye drops obtained the notice of clinical trial approval.
On July 25th, Gelonghui reported that Shenyang Xingqi Pharmaceutical (300573.SZ) has recently received a drug clinical trial approval notice for SQ-22031 eye drops issued by the National Medical Products Administration. SQ-22031 eye drops are category 1 biological products developed by our company for treatment. In clinical trials, it is intended to be used for (1) dry eye syndrome; (2) neurotrophic keratitis. Among them, indication (2) neurotrophic keratitis was included in the second batch of rare disease catalog in China in 2023. According to the relevant requirements for category 1 biological products for therapeutic use in the registration classification of biological products, the company has completed SQ-2.
Xingqi Pharmaceutical Gets Nod to Register Bromfenac Sodium Eye Drops; Shares Down 3%
Shenyang Xingqi Pharmaceutical (300573.SZ) has obtained a pharmaceutical registration certificate for Bromfenac Sodium Eye Drops.
On July 24th, Gelunhui reported that Shenyang Xingqi Pharmaceutical (300573.SZ) announced that it has recently received the "Drug Registration Certificate" for Sodium Bromfenac Eye Drops issued by the National Drug Administration. The product is an eye drop whose main component is Sodium Bromfenac. The Sodium Bromfenac Eye Drops approved by the company are multi-dose products, clinically indicated for symptomatic treatment of inflammatory diseases in the external and anterior segments of the eye: blepharitis, conjunctivitis, scleritis (including superficial scleritis), and postoperative inflammation.
Zhu Shaoxing disclosed the Q2 report of his fund, with a significant shareholding reduction in Kweichow Moutai (600519.SH).
Recently, Zhu Shaoxing, the star fund manager of Fund Manager, revealed the second quarter report of his fund holdings in 2024. Currently, Zhu Shaoxing only manages one fund, the Fuguo Tianhuicheng Growth Hybrid Fund, with a management scale of nearly RMB 27 billion as of the end of the second quarter.
The latest development of Zhu Shaoxing's shareholding has been exposed! He reduced his shareholding in Maotai for two consecutive quarters and increased his holdings in these companies continuously.
Continuously increasing or decreasing shareholdings of these stocks for five consecutive quarters.
Market Participants Recognise Shenyang Xingqi Pharmaceutical Co.,Ltd.'s (SZSE:300573) Revenues Pushing Shares 26% HigherNo Data
